Media, page-346

An excerpt from the end of the article:

Marc Voigt: Yeah, 2023 will be very exciting, but also 2022 is not over, so we expect a number of different news, and 2023, we’ll see more data, very important data and may highlight TACTI-003, a trial in first-line head and neck cancer. Potential readout is some time mid of next year. So, by our standards in the relative near-term. We will have additional data from TACTI-002, INSIGHT-003, we will provide regulatory updates, we will see the expansion of the pipeline. We will have hopefully also news from the variety of the different partners we are having in China. I mentioned Novartis, I mentioned Glaxo and others. So, there’s a lot to expect. And despite the difficult year, 2022, for the whole sector, I believe Immutep has a chance to deliver and show a difference in terms of quality, and we are very much looking forward to that.